I. TFRC and Blood–Brain Barrier Delivery
TFRC (transferrin receptor 1, CD71) is a transmembrane glycoprotein that exists on the cell surface as a dimer. Its physiological function is to bind iron-loaded transferrin (Tf-Fe) and enter the cell via clathrin-dependent endocytosis. After endosomal acidification, iron ions dissociate from transferrin and are transported to the cytoplasm, while the complex of apotransferrin and TFRC returns to the cell membrane through the recycling pathway.
Engineered antibodies or fusion molecules can bind specifically to TFRC and be recruited into the endothelial cell endocytic pathway. During endosomal sorting, such a molecule has three possible fates: transcytosis to the brain parenchyma side, recycling back to the blood side, or entry into the lysosome for degradation. On the basis of this mechanism, TFRC is exploited for blood–brain barrier shuttle molecules (BBB shuttles).
An overall diagram of Tf trafficking
II. Determinants of Delivery Efficiency
The efficiency of TFRC-mediated delivery is determined by two sets of factors.
The first set comprises receptor-side parameters. The number of TFRC molecules available on the membrane surface of brain microvascular endothelial cells, the receptor turnover rate, and the recycling efficiency jointly determine the endocytic flux. This flux sets an upper limit on the number of payload molecules that can be recruited per unit time, and it shapes both the slope and the saturation inflection point of the curve relating dose to brain-side delivery.
The second set comprises molecule-side parameters. The sorting direction of the payload within the endosome is sensitive to structural parameters such as the binding epitope, affinity, and valency of the molecule for TFRC, and this is why different engineered molecules differ in how efficiently they reach the brain parenchyma.
In vivo, the high concentration of endogenous transferrin competes with exogenous molecules for binding, rendering receptor occupancy and the molecular uptake process dose-dependent. These variables need to be measured stably in living models, and their causal link to delivery efficiency needs to be established.
Schematic illustrating three potential endocytic sorting routes that anti-TfR bispecifics may take within endothelial cells at the BBB. Upon receptor binding, (1) anti-TfR bispecifics may be recycled to the luminal side (blood), (2) transcytosed to the parenchyma (brain), or (3) sorted to the lysosome for degradation. (B–D) Greater retention of [111In]DOTA–anti-TfRA/control (Ctr) IgG high-affinity variant in vivo.
III. Impact of Species Differences on Evaluation
Binding of human candidate molecules to TFRC is epitope-selective. Amino acid sequence differences between human TFRC and mouse Tfrc alter the binding availability, the affinity range, and the receptor clustering propensity of the molecule, and thereby affect endocytic flux and the outcome of endosomal sorting.
When human TFRC and endogenous mouse Tfrc are both present in the same mouse, abnormal receptor dimer composition can occur, introducing competitive binding and diversion of endocytic routes. Such interference makes it difficult to attribute experimental results to a delivery process mediated by human TFRC. Verification of the mechanistic link between BBB shuttle engineering parameters and brain-side delivery behavior therefore requires an in vivo model in which the human TFRC receptor system dominates.
The intracellular trafficking pathway of transferrin
VeloGene offers QuickMice™ hTFRC humanized mice for exactly this setting. Following the knock-in replacement approach, the human TFRC coding sequence is introduced in place of the endogenous mouse Tfrc coding exons, with the mouse gene disrupted, so that the human receptor — rather than a mixture of human and mouse receptors — defines the binding availability, affinity window and endosomal sorting behavior measured in vivo. Built on the TurboMice™ high-efficiency tetraploid complementation technology platform, VeloGene can rapidly, precisely and at scale customize humanized mouse models according to customer requirements, shortening the path from BBB shuttle engineering parameters to in vivo proof of brain delivery. Investigators are welcome to inquire.
References
- Mayle KM, Le AM, Kamei DT. The intracellular trafficking pathway of transferrin. Biochim Biophys Acta. 2012;1820(3):264-281.
- Yu YJ, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3(84):84ra44.
- Niewoehner J, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81(1):49-60.
- Bien-Ly N, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med. 2014;211(2):233-244.
- Wiley DT, et al. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A. 2013;110(21):8662-8667.
